Omeros Co. (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Omeros Co. (NASDAQ:OMER) have received a consensus recommendation of “Moderate Buy” from the five analysts that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $22.50.

A number of brokerages have weighed in on OMER. Cantor Fitzgerald reiterated a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price target on shares of Omeros in a report on Thursday, February 20th. StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a research report on Thursday. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research report on Friday, January 17th. Finally, RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a report on Thursday, November 14th.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Truvestments Capital LLC grew its stake in Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 1,669 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Omeros by 79.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 1,972 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Omeros in the 4th quarter valued at approximately $46,000. Picton Mahoney Asset Management grew its holdings in Omeros by 692.5% during the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 4,404 shares during the last quarter. Finally, US Bancorp DE purchased a new position in Omeros during the fourth quarter worth $81,000. 48.79% of the stock is owned by hedge funds and other institutional investors.

Omeros Trading Up 8.4 %

Shares of NASDAQ OMER opened at $8.01 on Friday. Omeros has a twelve month low of $2.61 and a twelve month high of $13.60. The stock has a 50 day moving average of $8.90 and a two-hundred day moving average of $7.12. The stock has a market cap of $464.18 million, a P/E ratio of -3.47 and a beta of 2.03.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.